AX-2026-043343

N-Acetyl Semax Amide · 10 mg declared · WuXi TIDES (WuXi AppTec Testing Division) · lot WXT-2505-J2528

FAILPURITY ONLY

Report ID: AX-2026-043343
Compound: N-Acetyl Semax Amide
Compound class: Neuroactive and cognitive peptides
Supplier: WXT — WuXi TIDES (WuXi AppTec Testing Division)
Batch / lot: WXT-2505-J2528
Declared label claim: 10mg
Laboratory: Medutest
Assay date: 21 Dec 2025
Submitted: 06 Jan 2026
Quarter: 2025-Q4
Submitter: survodutide_mixup
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the neuroactive and cognitive peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	98.30	% area	≥ 98.5	FAIL
Total impurities	RP-HPLC, sum of reported peaks	1.70	% area	≤ 1.5	FAIL
Largest single impurity	RP-HPLC — Met sulfoxide (+16 Da)	0.95	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	5.11	%	≤ 12.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.92	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.57	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.07	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	6.46	min	6.45 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.19	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	66,884	—	≥ 20,000	PASS
Resolution to nearest impurity	vs N-acetyl semax free acid (+1 Da)	1.79	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 66,884, and skew follows the reported asymmetry factor of 1.19. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.95 % impurity against a 98.30 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	N-Acetyl Semax Amide — main peak	6.46	4,777,685	98.30	—
2	Met sulfoxide (+16 Da)	6.18	46,173	0.95	+15.995
3	des-acetyl amide (−42 Da)	6.13	15,067	0.31	-42.011
4	semax (des-acetyl, des-amide, −41 Da)	5.99	11,665	0.24	-41.027
5	N-acetyl semax free acid (+1 Da)	6.64	9,721	0.20	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.65	98.30	divergence +0.25 pp vs batch median
Total impurities (% area)	1.35	1.70
Largest single impurity (% area)	0.61	0.95
Water (%)	not stated	5.11
Counter-ion (%)	not stated	5.92
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 24 d) → laboratory (courier, dry ice, 7 d) → assay.
Assay date: 21 Dec 2025
Submitted to the index: 06 Jan 2026
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

macrolactam06 Jan 2026

Where the sequence is cyclised, the uncyclised precursor elutes early and is easy to mistake for a truncation. The mass distinguishes the two and this record carries one, so the check costs nothing.

lal_assay06 Jan 2026

I am sceptical of unstated methods generally and of unmeasured properties specifically. This is the second kind, and it is the more honest of the two failure modes.

esi_tof06 Jan 2026

The status field reads PURITY ONLY, which is precisely what the record is. Nothing is being withheld and nothing is being implied.

Section 7

Related records

Same batch — lot WXT-2505-J2528 n=7

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2025-020905	WXT-2505-J2528	VendorInvestigate	2025-Q4	98.20	6.21	104.9	Buyer-sourced	FAIL
AX-2026-043342	WXT-2505-J2528	Janoshik	2025-Q4	98.40	5.53	—	Buyer-sourced	FAIL
AX-2025-020906	WXT-2505-J2528	Kestrel	2025-Q4	98.65	6.10	—	Laboratory-retained	PASS
AX-2025-020907	WXT-2505-J2528	Janoshik	2025-Q4	98.24	6.01	98.7	Buyer-sourced	FAIL
AX-2025-020908	WXT-2505-J2528	Kestrel	2025-Q4	98.85	6.24	106.7	Buyer-sourced	PASS
AX-2025-020909	WXT-2505-J2528	Janoshik	2025-Q4	98.72	5.25	—	Supplier-supplied	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent N-Acetyl Semax Amide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043327	CPC	CPC-2602-D1905	Nordanalyt	2026-Q3	99.05	5.67	90.6	Buyer-sourced	1	FAIL
AX-2026-043328	CPC	CPC-2602-D1905	Janoshik	2026-Q3	99.49	6.83	100.9	Supplier-supplied	0	PASS
AX-2026-043331	CPC	CPC-2602-D1905	Janoshik	2026-Q3	99.46	6.22	—	Supplier-supplied	0	PASS
AX-2026-043329	CPC	CPC-2602-D1905	Janoshik	2026-Q3	98.56	5.44	—	Buyer-sourced	0	PASS
AX-2026-043330	CPC	CPC-2602-D1905	Janoshik	2026-Q3	98.65	5.70	91.4	Laboratory-retained	0	PASS
AX-2026-043326	CPC	CPC-2602-D1905	VendorInvestigate	2026-Q3	98.93	5.74	107.0	Buyer-sourced	0	PASS
AX-2026-042484	Homopeptide	HOMO-2603-C5267	Janoshik	2026-Q2	99.17	8.61	92.1	Buyer-sourced	0	PASS
AX-2026-042488	Homopeptide	HOMO-2603-C5267	PeptideMeter	2026-Q2	98.83	8.48	—	Buyer-sourced	0	PASS

Other recent WXT records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043376	Semaglutide	WXT-2604-C3248	Janoshik	2026-Q3	97.08	4.22	—	Buyer-sourced	1	MARGINAL
AX-2026-043429	L-Glutathione (reduced)	WXT-2605-B3833	Nordanalyt	2026-Q3	98.48	6.58	96.9	Supplier-supplied	1	FAIL
AX-2026-043347	Leuprolide	WXT-2604-K2596	PeptideMeter	2026-Q3	99.16	5.99	93.6	Buyer-sourced	0	PASS
AX-2026-043353	Leuprolide	WXT-2604-K2596	Janoshik	2026-Q3	99.19	4.90	95.3	Laboratory-retained	0	PASS
AX-2026-043345	Leuprolide	WXT-2604-K2596	Janoshik	2026-Q3	98.93	5.28	—	Buyer-sourced	0	PASS
AX-2026-043424	L-Glutathione (reduced)	WXT-2605-B3833	PeptideMeter	2026-Q3	98.37	6.86	—	Buyer-sourced	0	FAIL
AX-2026-043374	Semaglutide	WXT-2604-C3248	Janoshik	2026-Q3	97.00	3.56	—	Buyer-sourced	1	MARGINAL
AX-2026-043377	Semaglutide	WXT-2604-C3248	PeptideMeter	2026-Q3	97.20	4.08	—	Buyer-sourced	1	MARGINAL